Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Maoyan Entertainment (猫眼娱乐) IPO: Turning Profitable, Thoughts on Valuation

ECM Weekly (26 January 2019) - Maoyan, CStone Pharma, Polycab India, Hujiang Edu

ECM Weekly (2 February 2019) - Maoyan, China Tower, Dexin, Chalet Hotels, Bharat Hotels, Wingarc1st

Entertainment Plus (猫眼娱乐) IPO: The Engineered Movie Ticketing Leader that Runs Out of Steam (Part 1)

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Maoyan Entertainment / Equity Capital Markets

<p>In our previous insight, we talked about the fundamentals of Entertainment Plus, the largest online movie ticketing platform in China. In this insight, we will touch upon the analysis of the value chain for Entertainment Plus, in particular, the cinema chains in China, and the impact of a potentially material regulatory change that could sink the company. We will also provide our initial thought on the company's valuation. </p>

In our previous insight, we talked about the fundamentals of Entertainment Plus, the largest online movie ticketing platform in China. In this insight, we will touch upon the analysis of the value chain for Entertainment Plus, in particular, the cinema chains in China, and the impact of a potentially material regulatory change that could sink the company. We will also provide our initial thought on the company's valuation. 

Entertainment Plus (猫眼娱乐) IPO: The Coming Regulatory Bang Isn't That Bad (Part 2)